IBDEI0W8 ; ; 06-AUG-2015
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;JUN 29, 2015
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,15662,0)
 ;;=204.10^^81^946^16
 ;;^UTILITY(U,$J,358.3,15662,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,15662,1,4,0)
 ;;=4^204.10
 ;;^UTILITY(U,$J,358.3,15662,1,5,0)
 ;;=5^CLL w/o Remission
 ;;^UTILITY(U,$J,358.3,15662,2)
 ;;=^267523
 ;;^UTILITY(U,$J,358.3,15663,0)
 ;;=204.11^^81^946^18
 ;;^UTILITY(U,$J,358.3,15663,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,15663,1,4,0)
 ;;=4^204.11
 ;;^UTILITY(U,$J,358.3,15663,1,5,0)
 ;;=5^CLL,In Remission
 ;;^UTILITY(U,$J,358.3,15663,2)
 ;;=^267524
 ;;^UTILITY(U,$J,358.3,15664,0)
 ;;=201.90^^81^946^83
 ;;^UTILITY(U,$J,358.3,15664,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,15664,1,4,0)
 ;;=4^201.90
 ;;^UTILITY(U,$J,358.3,15664,1,5,0)
 ;;=5^Hodgkin's Lymphoma, Unpsec Type & Site
 ;;^UTILITY(U,$J,358.3,15664,2)
 ;;=^267430
 ;;^UTILITY(U,$J,358.3,15665,0)
 ;;=785.6^^81^946^89
 ;;^UTILITY(U,$J,358.3,15665,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,15665,1,4,0)
 ;;=4^785.6
 ;;^UTILITY(U,$J,358.3,15665,1,5,0)
 ;;=5^Lymphadenopathy
 ;;^UTILITY(U,$J,358.3,15665,2)
 ;;=^72368
 ;;^UTILITY(U,$J,358.3,15666,0)
 ;;=200.20^^81^946^90
 ;;^UTILITY(U,$J,358.3,15666,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,15666,1,4,0)
 ;;=4^200.20
 ;;^UTILITY(U,$J,358.3,15666,1,5,0)
 ;;=5^Lymphoma,Burkitt's,Site Unspec
 ;;^UTILITY(U,$J,358.3,15666,2)
 ;;=^17529
 ;;^UTILITY(U,$J,358.3,15667,0)
 ;;=202.00^^81^946^92
 ;;^UTILITY(U,$J,358.3,15667,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,15667,1,4,0)
 ;;=4^202.00
 ;;^UTILITY(U,$J,358.3,15667,1,5,0)
 ;;=5^Lymphoma,Low-Grade,Site Unspec
 ;;^UTILITY(U,$J,358.3,15667,2)
 ;;=^72606
 ;;^UTILITY(U,$J,358.3,15668,0)
 ;;=200.10^^81^946^91
 ;;^UTILITY(U,$J,358.3,15668,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,15668,1,4,0)
 ;;=4^200.10
 ;;^UTILITY(U,$J,358.3,15668,1,5,0)
 ;;=5^Lymphoma,Int or High Grade,Site Unspec
 ;;^UTILITY(U,$J,358.3,15668,2)
 ;;=^175886
 ;;^UTILITY(U,$J,358.3,15669,0)
 ;;=273.3^^81^946^93
 ;;^UTILITY(U,$J,358.3,15669,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,15669,1,4,0)
 ;;=4^273.3
 ;;^UTILITY(U,$J,358.3,15669,1,5,0)
 ;;=5^Macroglobulinemia
 ;;^UTILITY(U,$J,358.3,15669,2)
 ;;=^73013
 ;;^UTILITY(U,$J,358.3,15670,0)
 ;;=203.00^^81^946^103
 ;;^UTILITY(U,$J,358.3,15670,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,15670,1,4,0)
 ;;=4^203.00
 ;;^UTILITY(U,$J,358.3,15670,1,5,0)
 ;;=5^Multiple Myeloma w/o Remission
 ;;^UTILITY(U,$J,358.3,15670,2)
 ;;=^267514
 ;;^UTILITY(U,$J,358.3,15671,0)
 ;;=203.01^^81^946^105
 ;;^UTILITY(U,$J,358.3,15671,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,15671,1,4,0)
 ;;=4^203.01
 ;;^UTILITY(U,$J,358.3,15671,1,5,0)
 ;;=5^Multiple Myeloma,In Remission
 ;;^UTILITY(U,$J,358.3,15671,2)
 ;;=^267515
 ;;^UTILITY(U,$J,358.3,15672,0)
 ;;=238.6^^81^946^108
 ;;^UTILITY(U,$J,358.3,15672,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,15672,1,4,0)
 ;;=4^238.6
 ;;^UTILITY(U,$J,358.3,15672,1,5,0)
 ;;=5^Plasmacytoma NOS
 ;;^UTILITY(U,$J,358.3,15672,2)
 ;;=^81973
 ;;^UTILITY(U,$J,358.3,15673,0)
 ;;=205.00^^81^946^4
 ;;^UTILITY(U,$J,358.3,15673,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,15673,1,4,0)
 ;;=4^205.00
 ;;^UTILITY(U,$J,358.3,15673,1,5,0)
 ;;=5^AML w/o Remission
 ;;^UTILITY(U,$J,358.3,15673,2)
 ;;=^267531
 ;;^UTILITY(U,$J,358.3,15674,0)
 ;;=205.01^^81^946^6
 ;;^UTILITY(U,$J,358.3,15674,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,15674,1,4,0)
 ;;=4^205.01
 ;;^UTILITY(U,$J,358.3,15674,1,5,0)
 ;;=5^AML,In Remission
 ;;^UTILITY(U,$J,358.3,15674,2)
 ;;=^267532
 ;;^UTILITY(U,$J,358.3,15675,0)
 ;;=205.10^^81^946^19
 ;;^UTILITY(U,$J,358.3,15675,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,15675,1,4,0)
 ;;=4^205.10
 ;;
 ;;$END ROU IBDEI0W8
